For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Anaptysbio, Inc.

Calculating rank

USPTO Granted Patents = 23

CIPO Patents = 3

EPO Patents = 5

Trademarks = 2

Forward Citations = 82

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

David J King (17 out of 54 patents)

Peter M Bowers (11 out of 11 patents)

Robert A Horlick (10 out of 15 patents)

4. Marilyn Kehry (8 out of 14 patents)

5. Andrew John McKnight (6 out of 7 patents)

6. Marco Londei (4 out of 5 patents)

7. Andrew B Cubitt (4 out of 19 patents)

8. Jean Da Silva Correia (2 out of 2 patents)

9. Baochuan Huang (2 out of 2 patents)

10. Tamlyn Yee Neben (2 out of 2 patents)

11. Rupal Kalapanda (2 out of 2 patents)

12. Xue Zhang (1 out of 6 patents)

13. Helen Toni Jun (1 out of 4 patents)

14. Jennifer Dalton (1 out of 1 patent)

15. Betty Wu (1 out of 1 patent)

23 patents: Sort by Forward Citations

1. 12742010 - PD-1 AGONIST AND METHOD OF USING SAME (2026-09-22),

2. 12715924 - METHOD OF TREATING ICHTHYOSIS IN A SUBJECT BY ADMINISTERING AN ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) BINDING AGENT (2026-08-25),

3. 12391761 - Antibodies directed against interleukin 36 receptor (IL-36R) (2025-08-19),

4. 11999783 - Method of treating autoimmune disease with antibodies against IL-33 (2024-06-04),

5. 11753472 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2023-09-12),

6. 11352427 - Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3) (2022-06-07),

7. 11155624 - Antibodies directed against programmed death-1 (PD-1) (2021-10-26),

8. 11130814 - Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) (2021-09-28),

9. 10836824 - Antibodies directed against lymphocyte activation gene 3 (LAG-3) (2020-11-17),

10. 10836820 - Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33) (2020-11-17),

11. 10738117 - Antibodies directed against programmed death-1 (PD-1) (2020-08-11),

12. 10526410 - Antibodies directed against interleukin 36 receptor (IL-36R) (2020-01-07),

13. 10508149 - Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) (2019-12-17),

14. 10059764 - Antibodies directed against interleukin-33 (IL-33) and methods of making and using (2018-08-28),

15. 9951126 - Antibodies directed against nerve growth factor (NGF) (2018-04-24),

Company Overview

Anaptysbio, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative therapeutic antibodies. The company focuses on harnessing its proprietary technology platform to create treatments for various diseases, particularly in the fields of immunology and oncology. Anaptysbio is committed to advancing its pipeline of drug candidates through rigorous research and development, aiming to address unmet medical needs and improve patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

23 Patents

#263 in San Diego, CA

#3,426 in California

#14,456 in US

#27,744 in the World

San Diego, CA, United States of America

Anaptysbio, Inc.

Forward Citations = 82

30 inventors:

David J King (17 out of 54 patents)

Peter M Bowers (11 out of 11 patents)

Robert A Horlick (10 out of 15 patents)

4. Marilyn Kehry (8 out of 14 patents)

5. Andrew John McKnight (6 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anaptysbio, Inc.. Retrieved from https://idiyas.com/company/anaptysbio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…